Compare ALIS & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALIS | UNCY |
|---|---|---|
| Founded | 2024 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.9M | 100.6M |
| IPO Year | 2024 | 2021 |
| Metric | ALIS | UNCY |
|---|---|---|
| Price | $8.70 | $3.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $28.40 |
| AVG Volume (30 Days) | 10.8K | ★ 1.0M |
| Earning Date | 01-01-0001 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10,044.55 |
| P/E Ratio | $209.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.27 | $3.33 |
| 52 Week High | $14.91 | $8.74 |
| Indicator | ALIS | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 39.63 | 42.19 |
| Support Level | $7.70 | $3.34 |
| Resistance Level | $10.17 | $4.18 |
| Average True Range (ATR) | 0.87 | 0.21 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 55.62 | 40.00 |
Calisa Acquisition Corp is a blank check company with the purpose of effecting a merger, asset acquisition, stock exchange, stock purchase, reorganization, or similar business combination.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.